Shanghai Fosun Chairman Budgets Half Of IPO Millions For Acquisitions
This article was originally published in PharmAsia News
Shanghai Fosun Pharmaceutical Chairman Chen Qiyu believes his company, already China's largest drug maker, is now poised to compete on the international market thanks to its recent initial public offering in Hong Kong.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.